CBD oil shows no surrogate evidence of drug interactions with opioids or benzodiazepines in advanced cancer patients

A randomized controlled trial examined potential drug-drug interactions between CBD oil and concomitant medications in advanced cancer patients participating in the MedCan-1 parent study for symptom control. The study used surrogate measures rather than direct pharmacokinetic assessments, evaluating whether CBD influenced the maximum dose of oil self-selected by patients in relation to specific medication classes, and whether it increased the occurrence of adverse effects when taken with medications of interest.

The main findings showed no evidence from these surrogate measures that CBD increased the likelihood of developing adverse effects or influenced self-selected CBD dose in relation to opioid use or medications including benzodiazepines and antipsychotics. Participants taking paracetamol tolerated higher doses of CBD, though specific effect sizes and absolute numbers were not reported. Safety data including adverse events, serious adverse events, and discontinuations were not reported in the available information.

Key limitations include the use of surrogate measures rather than direct pharmacokinetic or clinical outcome measures of drug interactions. The findings are specific to the context of the parent study for symptom control in advanced cancer patients and short-term use. The discussion suggests concerns about clinically significant drug interactions 'may be unfounded' but this conclusion is based on limited surrogate endpoints. Practice relevance should be interpreted cautiously as the evidence does not establish causation and comes from indirect measures.